Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -13.16K | -12.36K | -4.97K | 0.00 | EBIT |
0.00 | -54.12M | -65.06M | -53.58M | -105.76K | EBITDA |
0.00 | -54.11M | -65.05M | -53.63M | -90.84K | Net Income Common Stockholders |
-120.68B | -36.01M | -64.51M | -53.64M | -90.84K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
448.03B | 511.01M | 72.11M | 8.04M | 1.34M | Total Assets |
477.93B | 526.54M | 76.84M | 9.68M | 116.63M | Total Debt |
2.83M | 3.81M | 282.58K | 15.00M | 58.06K | Net Debt |
-177.60M | -447.36M | -39.22M | 6.96M | -1.28M | Total Liabilities |
24.54B | 13.05M | 8.08M | 21.33M | 4.15M | Stockholders Equity |
446.83B | 495.68M | 48.90M | -11.65M | 112.48M |
Cash Flow | Free Cash Flow | |||
-117.11B | -43.06M | -55.91M | -35.23M | -316.69K | Operating Cash Flow |
-116.59B | -42.78M | -55.89M | -35.18M | -316.69K | Investing Cash Flow |
-205.60B | -25.18M | -32.34M | -50.71K | -115.00M | Financing Cash Flow |
51.31B | 479.70M | 119.69M | 43.26M | 116.65M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $2.36B | ― | -31.68% | ― | 32.29% | 64.39% | |
52 Neutral | $5.38B | 3.59 | -41.63% | 2.87% | 17.72% | 1.87% | |
50 Neutral | $2.41B | ― | -93.55% | ― | 97.02% | 64.32% | |
48 Neutral | $3.10B | ― | -32.02% | ― | ― | -0.12% | |
45 Neutral | $2.62B | ― | -74.17% | ― | ― | -43.10% | |
41 Neutral | $2.51B | ― | -25.24% | ― | ― | -147.80% | |
40 Underperform | $2.32B | ― | 78.99% | ― | 2270.58% | 46.82% |
On April 29, 2025, MoonLake Immunotherapeutics will present an investor presentation during its Capital Markets Day event, detailing the company’s financial position, upcoming clinical developments, and strategic outlook. This presentation aims to provide stakeholders with insights into the company’s future direction and operational strategies, potentially impacting its market positioning and investor relations.
Spark’s Take on MLTX Stock
According to Spark, TipRanks’ AI Analyst, MLTX is a Neutral.
MoonLake Immunotherapeutics presents a high-risk, high-reward scenario typical for early-stage biotech firms. The strong balance sheet and recent financing provide a solid financial foundation, but the lack of revenue and operational losses weigh heavily on the score. Technical indicators are mixed, and the negative valuation metrics reflect the developmental nature of the company. The significant financing event is a positive catalyst, enhancing the company’s ability to advance its pipeline.
To see Spark’s full report on MLTX stock, click here.
On March 31, 2025, MoonLake Immunotherapeutics entered into a loan and security agreement with Hercules Capital for up to $500 million in non-dilutive financing. This agreement, which includes a $75 million initial draw, aims to support the company’s growth, including the advancement of sonelokimab and its expected launch in 2027. The financing enhances MoonLake’s financial position, allowing it to progress its clinical trials and prepare for commercial readiness without diluting shareholder equity. The company plans to provide further updates on its clinical programs and financial strategies at a Capital Markets Update on April 29, 2025.